Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current problems with non-specific COX inhibitors.

P McGettigan1, D Henry

  • 1Discipline of Clinical Pharmacology, School of Population Health Sciences, Faculty of Medicine and Health Sciences, The University of Newcastle, New South Wales, Australia. gmcgetti@mail.newcastle.edu.au

Current Pharmaceutical Design
|December 5, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlation of serum level of squamous cell carcinoma antigen with severity of cutaneous psoriasis, assessed using the simplified psoriasis index.

Annales de dermatologie et de venereologie·2024
Same author

Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Tolerancing and characterization of curved image sensor systems.

Applied optics·2020
Same author

Urticarial eruption in COVID-19 infection.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

Selective RET kinase inhibition for patients with RET-altered cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

On three-dimensional Gerstner-like equatorial water waves.

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2017
Same journal

Precision Nanotechnology in Oral Oncology: From Biomarker-Guided Targeting to AI-Driven Theranostics.

Current pharmaceutical design·2026
Same journal

Pharmacological Insights into Medicinal Plants and Phytomolecules for the Management of Alopecia with Mechanistic Perspectives and Therapeutic Potential.

Current pharmaceutical design·2026
Same journal

Addressing Challenges, Regulatory Shifts, and the Need for Cost-Effective Alternatives for Complex Topical Formulations.

Current pharmaceutical design·2026
Same journal

The Mechanism of Huaiqihuang in the Treatment of Nephrotic Syndrome: An Integrated Study Based on Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation, and Experimental Validation.

Current pharmaceutical design·2026
Same journal

Resveratrol and the NLRP3 Inflammasome: Unlocking the Anti-inflammatory Potential of a Natural Compound.

Current pharmaceutical design·2026
Same journal

The Use of Hemostatic Agents in Traumatic Bleeding: One Size Does Not Fit All.

Current pharmaceutical design·2026
See all related articles

Non-steroidal anti-inflammatory drugs (NSAIDs) effectively treat pain and inflammation but carry significant risks. Understanding their mechanism of action, cyclo-oxygenase (COX) inhibition, is key to managing NSAID toxicity in the gastrointestinal, cardiac, and renal systems.

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Nephrology
  • Cardiology

Background:

  • Non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed for pain and inflammation.
  • NSAIDs exhibit significant toxicity, primarily affecting the gastrointestinal, cardiac, and renal systems.
  • The common mechanism of action for NSAIDs involves the inhibition of cyclo-oxygenase (COX) enzymes, which contributes to both therapeutic effects and toxicity.

Purpose of the Study:

  • To describe the main predictable gastrointestinal, cardiac, and renal toxicities associated with conventional NSAIDs.
  • To review the clinical and epidemiological evidence supporting these NSAID-induced toxicities.
  • To highlight patient populations at higher risk for NSAID-related adverse events.

Main Methods:

Related Experiment Videos

  • Review of clinical and epidemiological evidence.
  • Analysis of NSAID mechanism of action, specifically COX inhibition.
  • Identification of risk factors for NSAID toxicity.

Main Results:

  • NSAID toxicity includes gastrointestinal issues (ulceration, bleeding, perforation) and cardiac and renal complications.
  • Gastrointestinal side effects are often local and systemic, with the upper GI tract being more commonly affected.
  • Cardiac and renal toxicities are more probable in patients with pre-existing conditions, as prostaglandins are vital for homeostasis.

Conclusions:

  • Conventional NSAIDs, by inhibiting both COX-1 and COX-2, can lead to significant gastrointestinal, cardiac, and renal adverse effects.
  • Elderly patients, those with a history of ulcers or bleeding, and individuals with cardiac disease are at the highest risk.
  • Prescribing NSAIDs necessitates a careful balance of potential benefits against harms, particularly in high-risk individuals.